Drug maker Astellas will let 340B covered entities count accumulations of an injectable form of its antifungal drug Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, provided the entities use a “compliant 340B inventory replenishment model,” the company said in a public notice late last week.
Astellas updated the NDC on Cresemba’s 372mg intravenous formulation on Feb. 20, according to a notice posted late last week on the U.S. Health Resources and Services Administration (HRSA) website.
Drug maker Astellas will let 340B covered entities count accumulations of an injectable form of its antifungal drug Cresemba under its old National Drug Code toward replenishment of equal quantities under the product’s corresponding new NDC, provided the entities use […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.